MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has appointed Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer, bringing on a seasoned financial leader to guide the company through a crucial stage as its lead candidate, buntanetap, advances in late-stage clinical development.
Guerin joins Annovis with more than two decades of financial leadership in biopharma. Most recently, he served as CFO of Onconova Therapeutics, now Traws Pharma, Inc. (Nasdaq: TRAW), where he oversaw multiple financing transactions, including public offerings and a $20 million raise in 2024. He also guided the company through its merger with Trawsfynydd Therapeutics, strengthening its pipeline in virology and oncology.
Earlier in his career, Guerin held senior finance roles at Cardiokine, Inc. and Barrier Therapeutics, Inc., where he played a key role in drug approval and IPO processes. He began his career at Coopers & Lybrand in Philadelphia and holds CPA, CMA, and CFM certifications.
“I am very excited to join the Annovis team at this critical juncture for the company and for patients with neurodegenerative diseases,” Guerin said. “Buntanetap has demonstrated efficacy in smaller trials and is on track to replicate that success in larger, registrational clinical studies.”
With Guerin’s appointment, Annovis strengthens its financial leadership as it works to advance buntanetap toward potential commercialization, aiming to deliver a new therapeutic option for patients with neurodegenerative diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.